Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial

INTRODUCTION: Maintenance of drug efficacy and safety over the long term is important to investigate for progressive conditions like type 2 diabetes mellitus (T2DM). This study aimed to evaluate whether efficacy of dapagliflozin added to glimepiride observed at 24 weeks was maintained at 48 weeks, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Strojek, Krzysztof, Yoon, Kun-Ho, Hruba, Veronika, Sugg, Jennifer, Langkilde, Anna Maria, Parikh, Shamik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065289/
https://www.ncbi.nlm.nih.gov/pubmed/24920277
http://dx.doi.org/10.1007/s13300-014-0072-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065289/
https://www.ncbi.nlm.nih.gov/pubmed/24920277
http://dx.doi.org/10.1007/s13300-014-0072-0

Ejemplares similares